![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: VGLL3 |
Gene summary for VGLL3 |
![]() |
Gene information | Species | Human | Gene symbol | VGLL3 | Gene ID | 389136 |
Gene name | vestigial like family member 3 | |
Gene Alias | VGL-3 | |
Cytomap | 3p12.1 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A8MV65 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
389136 | VGLL3 | ATC11 | Human | Thyroid | ATC | 1.21e-05 | 5.21e-01 | 0.3386 |
389136 | VGLL3 | ATC13 | Human | Thyroid | ATC | 1.07e-15 | 2.76e-01 | 0.34 |
389136 | VGLL3 | ATC2 | Human | Thyroid | ATC | 3.07e-09 | 1.10e+00 | 0.34 |
389136 | VGLL3 | ATC3 | Human | Thyroid | ATC | 1.37e-10 | 6.53e-01 | 0.338 |
389136 | VGLL3 | ATC4 | Human | Thyroid | ATC | 4.13e-02 | 9.87e-02 | 0.34 |
389136 | VGLL3 | ATC5 | Human | Thyroid | ATC | 2.95e-12 | 3.02e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
VGLL3 | SNV | Missense_Mutation | novel | c.793N>T | p.Pro265Ser | p.P265S | A8MV65 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
VGLL3 | SNV | Missense_Mutation | rs368641887 | c.806N>T | p.Ala269Val | p.A269V | A8MV65 | protein_coding | tolerated(0.08) | benign(0.207) | TCGA-QS-A5YQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
VGLL3 | insertion | In_Frame_Ins | novel | c.810_811insGCATGTACACGTCATGCATATGGCTGT | p.Ala270_Arg271insAlaCysThrArgHisAlaTyrGlyCys | p.A270_R271insACTRHAYGC | A8MV65 | protein_coding | TCGA-B5-A11I-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD | ||
VGLL3 | insertion | Frame_Shift_Ins | novel | c.606_607insAGCAGAG | p.Val203SerfsTer5 | p.V203Sfs*5 | A8MV65 | protein_coding | TCGA-D1-A0ZR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
VGLL3 | deletion | Frame_Shift_Del | novel | c.31delC | p.Gln11SerfsTer35 | p.Q11Sfs*35 | A8MV65 | protein_coding | TCGA-EO-A3KX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
VGLL3 | deletion | Frame_Shift_Del | novel | c.473delC | p.Pro158HisfsTer54 | p.P158Hfs*54 | A8MV65 | protein_coding | TCGA-FI-A2D6-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
VGLL3 | SNV | Missense_Mutation | novel | c.921N>G | p.Ser307Arg | p.S307R | A8MV65 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-44-4112-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
VGLL3 | SNV | Missense_Mutation | c.572A>T | p.Asn191Ile | p.N191I | A8MV65 | protein_coding | tolerated(0.2) | benign(0.006) | TCGA-49-AAR2-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | taxol | CR | |
VGLL3 | SNV | Missense_Mutation | novel | c.285N>T | p.Gln95His | p.Q95H | A8MV65 | protein_coding | deleterious(0.04) | probably_damaging(0.995) | TCGA-55-7910-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
VGLL3 | SNV | Missense_Mutation | c.865T>A | p.Ser289Thr | p.S289T | A8MV65 | protein_coding | tolerated(1) | benign(0) | TCGA-62-A46O-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |